| Today's Big NewsMay 3, 2023 |
| By Annalee Armstrong Eli Lilly’s Alzheimer’s disease candidate has achieved a 35% slowing of cognitive decline and a 39% lower risk of advancing to the next stage of the disease when compared to placebo. |
|
|
|
By Gabrielle Masson Four years after taking the helm of Cerevel Therapeutics, Tony Coles, M.D., is stepping down, handing the reins over to Ron Renaud as the neuroscience biotech waits on seven data readouts. |
By Nick Paul Taylor The clock is ticking down to the FDA advisory committee meeting about Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy SRP-9001. With days to go, Sarepta has set out what is expected to be asked at the meeting—and made the case that it can allay concerns about its confirmatory trial. |
By Max Bayer Magenta Therapeutics has found a financial exit route months after going on the hunt for a sale, inking a reverse merger with Dianthus Therapeutics. Dianthus is a year removed from a $100 million series A. |
By Max Bayer Pfizer is axing a handful of midstage medicines, most of which stemmed from the company's acquisition of Arena Pharmaceuticals. Company executives also noted on its first-quarter earnings call that it remains on the M&A hunt even after acquiring Seagen for almost $50 billion. |
By Nick Paul Taylor Immatics has posted more evidence that PRAME may live up to its billing as “one of the most promising and most prevalent” solid tumor targets. In updated phase 1b data, the biotech reported a 64% response rate and early signs that its T-cell therapy may have deep and durable effects against cancer cells. |
By Annalee Armstrong Companies looking to execute decentralized clinical trials should watch out for data variability and precision as information comes in from patients’ homes or local healthcare facilities, according to new FDA guidance. But the agency is otherwise keen to see more of these studies to help boost diversity in clinical research. |
By Gabrielle Masson Convergent Therapeutics has circled up $90 million to develop next-gen radiopharmaceuticals in oncology, with its lead clinical program targeting prostate cancer. |
By Gabrielle Masson Incyte is whittling down its R&D pipeline, scrapping six discovery programs—one in a rare form of anemia and five in various cancers—to focus on eight remaining programs. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Angus Liu Workers at GSK’s Montrose facility in Scotland on Tuesday kicked off a series of strikes that will sequentially affect six of the company’s sites and last throughout May. |
By Conor Hale Casana—a startup describing itself as “the industry leader in monitoring heart health through smart toilets”—has received a green light for its Heart Seat to log users’ pulse rate and blood oxygen saturation. |
By Zoey Becker In a new lawsuit between oncology giants, Bristol Myers Squibb claims AstraZeneca willfully infringed a key Opdivo patent. |
By Dave Muoio The Biden administration said that its frequently contested pandemic requirement will run its course on May 11 for federal employees and contractors, while more information for CMS-certified healthcare facilities will be released “in the coming days.” |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we discuss how the healthcare industry is addressing its role in climate change. |
|
|---|
|
|
|
July 18-19, 2023 | Jersey City, NJ
Connect with senior PR and communications leaders from big pharma, small-mid size pharma, biotech and more to gain insights and best practices on daily challenges in the industry. Save $500 when you Register Today!
|
|
| eBookDiscover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
| Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| WhitepaperThis paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
